DOI:
10.1055/s-00000025
Hormone and Metabolic Research
LinksClose Window
References
Grey A, Bolland M, Gamble G, Wattie D, Horne A, Davidson J, Reid IR.
The peroxisome proliferator-activated receptor-{gamma} agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: A randomized, controlled trial.
J Clin Endocrinol Metab 2007; 92: 1305-1310
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.